New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:00 EDTFURX, SLXPFurex drug should not be seen as threat to Salix, says Piper Jaffray
Piper Jaffray believes Furiex's (FURX) receptor antagonist eluxadoline in diarrhea-predominant irritable bowel syndrome should not be seen as a threat to Salix's (SLXP) Xifaxan in IBS-D. Piper says eluxdaoline and Xifaxan are mechanistically very different and will be used differently. The firm views Salix as attractive and reiterates an Overweight rating on the stock with a $106 price target.
News For SLXP;FURX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use